GlaxoSmithKline to License Valentis GeneSwitch Technology | GenomeWeb

NEW YORK, April 12 – GlaxoSmithKline has agreed to non-exclusively license Valentis’ GeneSwitch gene regulation technology for its functional genomics research, the companies said Thursday.

The licensing agreement for GeneSwitch is the second in two months for Valentis, which first licensed the technology to Wyeth-Ayerst Laboratories in February. The GeneSwitch technology controls the expression of a gene in transgenic animals and cell cultures with a trigger that turns the expression of the gene on or off.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.